Ebdarokimab
drugOn this page
Also known as AK-101Ak101
Summary
Ebdarokimab (CHEMBL4650437) is a phase-3 clinical-stage antibody; indicated across 3 conditions including psoriasis and ulcerative colitis.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Antibody
- Indications: 3 conditions
- Clinical trials: 4
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4650437 |
| Name | Ebdarokimab |
| Type | Antibody |
| Max phase | 3 |
Also known as: AK-101, Ak101, AK101, Ebdarokimab, EBDAROKIMAB
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| psoriasis | 3 | MONDO:0005083 | EFO:0000676 |
| ulcerative colitis | 1 | MONDO:0005101 | EFO:0000729 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 4.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 1 |
| PHASE1/PHASE2 | 1 |
| PHASE2 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05120297 | PHASE3 | COMPLETED | A Phase 3 Study of Efficacy and Safety of AK101 in Subjects With Psoriasis |
| NCT04172233 | PHASE1/PHASE2 | COMPLETED | A Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis |
| NCT04173637 | PHASE2 | COMPLETED | Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis |
| NCT06281704 | PHASE1 | COMPLETED | A Study of AK101 in Subjects With Moderately to Severely Active Ulcerative Colitis |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: psoriasis